GSK4528287
/ GSK
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
April 07, 2026
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Active, not recruiting | Sponsor: GlaxoSmithKline | Recruiting ➔ Active, not recruiting
Enrollment closed • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
October 30, 2025
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK4528287 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: GlaxoSmithKline | Trial completion date: Sep 2026 ➔ Mar 2027 | Trial primary completion date: Oct 2025 ➔ Apr 2026
Trial completion date • Trial primary completion date • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
February 03, 2025
A First-time in Human (FTIH) Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GSK4528287 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=48 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting
Enrollment open • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
1 to 3
Of
3
Go to page
1